Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients

S. Jiang, Y. Yu, S. A. Venners, Y. Zhang, H. Xing, Xiaobin Wang, X. Xu

Research output: Contribution to journalArticle

Abstract

The development of essential hypertension (EH) and inter-individual differences in response to antihypertensive treatment may partly result from genetic heterogeneity. In this study, we conducted an investigation of the combined effects of 5, 10-methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase (MS) A2756G polymorphisms on baseline blood pressure (BP) and BP response to antihypertensive Benazepril treatment in 823 Chinese hypertensive patients with a fixed daily dosage of 10 mg for 15 consecutive days. When MTHFR C677T and MS A2756G polymorphisms were modelled together with adjustment for important covariates, only MTHFR C677T was associated with baseline systolic BP (SBP) (Β (s.e.)=2.84 (1.10), P=0.0096) or baseline diastolic BP (DBP) (Β (s.e.)=2.19 (0.65), P=0.0008). Modelled together with adjustment for important covariates, MTHFR C677T and MS A2756G polymorphisms were both independently associated with increased DBP response (baseline minus post-treatment) to Benazepril treatment (C677T: Β (s.e.)=1.58 (0.76), P=0.038; A2756G: Β (s.e.)=2.14 (0.89), P=0.016). Neither polymorphism was associated with SBP response to Benazepril treatment. There were no significant interactions or effect modification between MTHFR C677T and MS A2756G gene polymorphisms in models of baseline SBP, baseline DBP or DBP response to Benazepril treatment. Our results suggest that the effects of MTHFR C677T and MS A2756G gene polymorphisms may have pivotal roles in the aetiology of EH and BP response to Benazepril treatment.

Original languageEnglish (US)
Pages (from-to)172-177
Number of pages6
JournalJournal of Human Hypertension
Volume25
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Methylenetetrahydrofolate Reductase (NADPH2)
Blood Pressure
Genes
Antihypertensive Agents
Therapeutics
Genetic Heterogeneity
benazepril
Individuality

Keywords

  • Benazepril
  • homocysteine
  • MS
  • MTHFR
  • SNP

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. / Jiang, S.; Yu, Y.; Venners, S. A.; Zhang, Y.; Xing, H.; Wang, Xiaobin; Xu, X.

In: Journal of Human Hypertension, Vol. 25, No. 3, 03.2011, p. 172-177.

Research output: Contribution to journalArticle

@article{c2b996d86821499180dd87e57398ab07,
title = "Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients",
abstract = "The development of essential hypertension (EH) and inter-individual differences in response to antihypertensive treatment may partly result from genetic heterogeneity. In this study, we conducted an investigation of the combined effects of 5, 10-methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase (MS) A2756G polymorphisms on baseline blood pressure (BP) and BP response to antihypertensive Benazepril treatment in 823 Chinese hypertensive patients with a fixed daily dosage of 10 mg for 15 consecutive days. When MTHFR C677T and MS A2756G polymorphisms were modelled together with adjustment for important covariates, only MTHFR C677T was associated with baseline systolic BP (SBP) (Β (s.e.)=2.84 (1.10), P=0.0096) or baseline diastolic BP (DBP) (Β (s.e.)=2.19 (0.65), P=0.0008). Modelled together with adjustment for important covariates, MTHFR C677T and MS A2756G polymorphisms were both independently associated with increased DBP response (baseline minus post-treatment) to Benazepril treatment (C677T: Β (s.e.)=1.58 (0.76), P=0.038; A2756G: Β (s.e.)=2.14 (0.89), P=0.016). Neither polymorphism was associated with SBP response to Benazepril treatment. There were no significant interactions or effect modification between MTHFR C677T and MS A2756G gene polymorphisms in models of baseline SBP, baseline DBP or DBP response to Benazepril treatment. Our results suggest that the effects of MTHFR C677T and MS A2756G gene polymorphisms may have pivotal roles in the aetiology of EH and BP response to Benazepril treatment.",
keywords = "Benazepril, homocysteine, MS, MTHFR, SNP",
author = "S. Jiang and Y. Yu and Venners, {S. A.} and Y. Zhang and H. Xing and Xiaobin Wang and X. Xu",
year = "2011",
month = "3",
doi = "10.1038/jhh.2010.50",
language = "English (US)",
volume = "25",
pages = "172--177",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients

AU - Jiang, S.

AU - Yu, Y.

AU - Venners, S. A.

AU - Zhang, Y.

AU - Xing, H.

AU - Wang, Xiaobin

AU - Xu, X.

PY - 2011/3

Y1 - 2011/3

N2 - The development of essential hypertension (EH) and inter-individual differences in response to antihypertensive treatment may partly result from genetic heterogeneity. In this study, we conducted an investigation of the combined effects of 5, 10-methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase (MS) A2756G polymorphisms on baseline blood pressure (BP) and BP response to antihypertensive Benazepril treatment in 823 Chinese hypertensive patients with a fixed daily dosage of 10 mg for 15 consecutive days. When MTHFR C677T and MS A2756G polymorphisms were modelled together with adjustment for important covariates, only MTHFR C677T was associated with baseline systolic BP (SBP) (Β (s.e.)=2.84 (1.10), P=0.0096) or baseline diastolic BP (DBP) (Β (s.e.)=2.19 (0.65), P=0.0008). Modelled together with adjustment for important covariates, MTHFR C677T and MS A2756G polymorphisms were both independently associated with increased DBP response (baseline minus post-treatment) to Benazepril treatment (C677T: Β (s.e.)=1.58 (0.76), P=0.038; A2756G: Β (s.e.)=2.14 (0.89), P=0.016). Neither polymorphism was associated with SBP response to Benazepril treatment. There were no significant interactions or effect modification between MTHFR C677T and MS A2756G gene polymorphisms in models of baseline SBP, baseline DBP or DBP response to Benazepril treatment. Our results suggest that the effects of MTHFR C677T and MS A2756G gene polymorphisms may have pivotal roles in the aetiology of EH and BP response to Benazepril treatment.

AB - The development of essential hypertension (EH) and inter-individual differences in response to antihypertensive treatment may partly result from genetic heterogeneity. In this study, we conducted an investigation of the combined effects of 5, 10-methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase (MS) A2756G polymorphisms on baseline blood pressure (BP) and BP response to antihypertensive Benazepril treatment in 823 Chinese hypertensive patients with a fixed daily dosage of 10 mg for 15 consecutive days. When MTHFR C677T and MS A2756G polymorphisms were modelled together with adjustment for important covariates, only MTHFR C677T was associated with baseline systolic BP (SBP) (Β (s.e.)=2.84 (1.10), P=0.0096) or baseline diastolic BP (DBP) (Β (s.e.)=2.19 (0.65), P=0.0008). Modelled together with adjustment for important covariates, MTHFR C677T and MS A2756G polymorphisms were both independently associated with increased DBP response (baseline minus post-treatment) to Benazepril treatment (C677T: Β (s.e.)=1.58 (0.76), P=0.038; A2756G: Β (s.e.)=2.14 (0.89), P=0.016). Neither polymorphism was associated with SBP response to Benazepril treatment. There were no significant interactions or effect modification between MTHFR C677T and MS A2756G gene polymorphisms in models of baseline SBP, baseline DBP or DBP response to Benazepril treatment. Our results suggest that the effects of MTHFR C677T and MS A2756G gene polymorphisms may have pivotal roles in the aetiology of EH and BP response to Benazepril treatment.

KW - Benazepril

KW - homocysteine

KW - MS

KW - MTHFR

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=79951671454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951671454&partnerID=8YFLogxK

U2 - 10.1038/jhh.2010.50

DO - 10.1038/jhh.2010.50

M3 - Article

C2 - 20445573

AN - SCOPUS:79951671454

VL - 25

SP - 172

EP - 177

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 3

ER -